drugset / Trial / NCT05683600
Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older
Phase 3
Terminated
3000 enrolled
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd. · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is an international multicenter clinical trial, which is planned to be conducted in several research centers in China and Pakistan. A randomized, double-blind, placebo-controlled design will be conducted to evaluate the efficacy, safety of LYB001 against COVID-19 as a booster dose in China.
Timeline
- Start
- 2022-12-29
- Primary completion
- 2023-07-12
- Completion
- 2023-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LYB001 | Vaccine | 0.5 ml | Intramuscular |